Dendritic cell infiltration and prognosis of early stage breast cancer

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7466-7474

  Treilleux, Isabelle ^a   Blay, Jean Yves ^a,b,c,e   Bendriss Vermare, Nathalie ^b   Ray Coquard, Isabelle ^a   Bachelot, Thomas ^a,b   Guastolla, Jean Paul ^a   Bremond, Alain ^a   Goddard, Sophie ^a   Pin, Jean Jacques ^d   Bartfaelemy Dubois, Clarisse ^d   Lebecque, Serge ^d  

^a Department of Pathology ^*  (France)

^b INSERM   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d MERCK RESEARCH LABORATORIES   (United States)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD123 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; T6 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; CELL MIGRATION; DENDRITIC CELL; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; T LYMPHOCYTE;

EID: 9444265268     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0684     Document Type: Article

References (50)

1. Solomayer EF, Diel IJ, Salami G, et al. Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin Cancer Res 2001;7:4102-8.
2. Schnitt SJ. Traditional and newer pathologic factors. J Natl Cancer Inst Monogr 2001;(30):22-6.
3. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
4. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
5. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
6. Burnet FM. Immunological aspects of malignant disease. Lancet 1967;1:1171-4.
7. Keast D. Immunosurveillance and cancer. Lancet 1970;2:710-2.
8. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-9.
9. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (Lond) 2001;410:1107-11.
10. Pardoll DM. Immunology. Stress, NK receptors, and immune surveillance. Science (Wash DC) 2001;294:534-6.
11. Lanier LL. A renaissance for the tumor immunosurveillance hypothesis. Nat Med 2001;7:1178-80.
12. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001;106:271-4.
13. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999;190: 1417-26.
14. Lenner P, Wiklund F, Emdin SO, et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer 1999;79: 927-32.
15. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 1997;71: 343-71.
16. Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995;346:796-8.
17. Stewart TH, Tsai SC. The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer. Clin Exp Metastasis 1993;11:295-305.
18. Suzuki A, Masuda A, Nagata H, et al. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol 2002;196:37-43.
19. Lewko B, Zoltowska A, Stepinski J, Roszkiewicz A, Moszkowska G. Dendritic and cancer cells in the breast tumors-an immunohistochemical study: short communication. Med Sci Monit 2000;6:892-5.
20. Lespagnard L, Gancberg D, Rouas G, et al. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer 1999;84:309-14.
21. Furukawa T, Watanabe S, Kodama T, et al. T-zone histiocytes in adenocarcinoma of the lung in relation to postoperative prognosis. Cancer (Phila) 1985;56:2651-6.
22. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer (Phila) 1989;63:496-503.
23. Goldman SA, Baker E, Weyant RJ, et al. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 1998;124: 641-6.
24. Grouard G, Rissoan MC, Filgueira L, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997;185:1101-11.
25. Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 2001;194:1823-34.
26. Haller O, Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic 2002;3:710-7.
27. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature (Lond) 1998;392:245-52.
28. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191:411-6.
29. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2:151-61.
30. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science (Wash DC) 1999;283:1183-6.
31. Dubois B, Bridon JM, Fayette J, et al. Dendritic cells directly modulate B cell growth and differentiation. J Leukoc Biol 1999;66:224-30.
32. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002;195:F9-14.
33. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001;106:259-62.
34. de Saint-Vis B, Vincent J, Vandenabeele S, et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced on DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998;9:325-36.
35. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373-86.
36. Tsujitani S, Furukawa T, Tamada R, et al. Langerhans cells and prognosis in patients with gastric carcinoma. Cancer (Phila) 1987;59: 501-5.
37. Giannini A, Bianchi S, Messerini L, et al. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol Res Pract 1991;187:496-502.
38. Vicari AP, Ait-Yahia S, Chemin K, et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000;165:1992-2000.
39. Sharma S, Stolina M, Luo J, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000;164:4558-63.
40. Sharma S, Stolina M, Zhu L, et al. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2001;61:6406-12.
41. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001;61:2062-70.
42. Horny HP, Feller AC, Horst HA, Lennert K. Immunocytology of plasmacytoid T cells: marker analysis indicates a unique phenotype of this enigmatic cell. Hum Pathol 1987;18:28-32.
43. Zou W, Machelon V, Coulomb-L'Hermin A, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-46.
44. Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003;200:255-68.
45. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-9.
46. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
47. Kuwana M, Kaburaki J, Wright TM, Kawakami Y, Ikeda Y. Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 2001;31:2547-57.
48. Gilliet M, Liu YJ. Generation of human CDS T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002; 195:695-704.
49. Zou W, Borvak J, Wei S, et al. Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. Eur J Immunol 2001;31:3833-9.
50. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001;159:237-43.